Three different insiders at AgomAb Therapeutics NV (AGMB) bought stock on the same date, October 8th, 2026, and together they put $267,670 into the shares. The filings name Epstein David R, Kemula Pierre Thadee Victor and Knotnerus Tim Jasper. Purchases that land on one date from more than one name are the pattern that insider trackers tend to flag first.
AgomAb Therapeutics operates in biological products, excluding diagnostic substances. That is a sector where company level news arrives in discrete steps, and where the people closest to a program are the ones who see those steps before the market does. The filings themselves do not state a motive, and nothing here should be read as one.
What makes a cluster worth a second look is not the dollar amount on its own. It is the agreement. A single purchase can reflect one person's calendar, a vesting schedule, or a window that happened to open. Three people filing against the same transaction date is a harder thing to explain away as coincidence of timing.
David R Epstein appears in our tables as an individual filer rather than an institution, as do the other two names. Pierre Thadee Victor Kemula and Tim Jasper Knotnerus round out the group. All three purchases carry the same transaction date of October 8th, 2026, which is what pulls them together into a single cluster rather than three unrelated events spread across a quarter.
On price, AgomAb Therapeutics last changed hands at $9.08. That is the reference point against which the $267,670 commitment should be measured. Readers who want the per transaction prices and the share counts behind each of the three names will find them in the individual filings, and the timeline above lays out how this activity sits against the preceding three months.
The things worth weighing against a cluster buy are the usual ones. Insider purchases say something about what people with access are willing to do with their own money, but they say nothing about timing, and they do not price in what the company has to deliver next. A biological products developer carries binary risk at the program level, and three buyers on one date does not change that arithmetic. It also does not tell you whether the buying continues.
The other caution is size. $267,670 across three people is a real commitment but a modest one in absolute terms, and it should be read as a signal about conviction rather than as a position that moves the share register. The useful comparison is against what these same insiders have done before, which is exactly what the timeline is there to show.
Sources: Form 4 filings submitted to the Securities and Exchange Commission, reconciled against our own insider transaction tables and last traded price data.
Full insider history, buyer by buyer, is on our AgomAb Therapeutics NV (AGMB) company page.